

WFS1 L645P — Wolframin

Leucine → Proline at position 645. C-terminal ER-luminal (calcium binding. ClinVar Uncertain significance, AlphaMissense 0.827, DynaMut2 $\Delta\Delta G$ -0.10 kcal/mol (destabilising).

IDENTITY

Variant	L645P (p.Leucine645Proline)
DNA change	c.1934T>C
Gene · Protein	WFS1 · Wolframin (890 aa)
UniProt	O76024 · WFS1_HUMAN
ClinVar accession	VCV002672987
Amino acid change	Leucine (L) → Proline (P)

STRUCTURAL CONTEXT

AlphaFold model	AF-O76024-F1, v6
pLDDT at residue 645	83.75 HIGH CONFIDENCE
Domain	C-terminal ER-luminal (calcium binding, calmodulin, chaperone)
Position context	C-terminal luminal domain · position 645 projects into the ER lumen
IDR flag	No — pLDDT well above 50 threshold

Position 645 sits in the C-terminal luminal domain (residues 653–869), wolframin's largest soluble region. This domain projects into the ER lumen and is implicated in calcium handling, ER stress sensing, and protein–protein interactions with ATF6 and Na⁺/K⁺ ATPase β 1. The wild-type residue is medium hydrophobic (leucine — branched); the mutant is rigid/helix-breaking (proline — kinks backbone). The chemistry shift implies altered local packing, hydrogen-bonding, and/or electrostatics at this site.

COMPUTATIONAL PREDICTIONS

ALPHAMISSENSE

0.827

am_class: **likely pathogenic** —
threshold > 0.564

DYNAMUT2 $\Delta\Delta G$ **-0.1** kcal/mol

Destabilising · Job
178092146931

PLDDT (ALPHAFOLD)

83.75

high confidence

CLINICAL EVIDENCE

ClinVar classification	UNCERTAIN SIGNIFICANCE
Review status	criteria provided, multiple submitters, no conflicts
Last evaluated	2024/04/15 00:00
Inheritance	Inheritance pattern not specified in ClinVar entry; WFS1 has both AD and AR presentations.
WFS1 variant landscape	L645P is 1 of ~326 pathogenic-spectrum variants in WFS1 (out of 2,243 in ClinVar) <ul style="list-style-type: none">(no conditions catalogued)

RESEARCH PATH DECISION TREE

$\Delta\Delta G < 2$ + binding site affected → CATEGORY 3 – docking experiments $\Delta\Delta G 2-4$ → CATEGORY 2 – pharmacological chaperones $\Delta\Delta G > 4$ → CATEGORY 1 – gene therapy pLDDT < 50 → CATEGORY 5 – IDR, experimental only Stable fold + functional site hit → CATEGORY 4 – site-specific docking

Category 3/4 — Most Druggable

$|\Delta\Delta G|=0.10 < 2$ kcal/mol (fold intact) + AlphaMissense 0.827 confirms functional impact. Specific local contacts disrupted — priority for docking and pharmacological chaperone screening.

Wolframins fold survives this substitution ($|\Delta\Delta G|=0.10$ kcal/mol). The pathogenic signal is real — AlphaMissense places it at 0.827. Protein still folds, but a specific local site is broken. Pharmacological chaperones and small-molecule binders are the rational therapeutic vector.